Loading...
Loading...
Tekmira
Pharmaceuticals Corporation
TKMRTKM, a leading developer of
RNA interference (RNAi) therapeutics, today announced that the U.S. Department
of Defense (DoD) has extended the period of a temporary stop-work order with
respect to Tekmira's TKM-Ebola program.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in